Leo Saldain

Leo Saldain

Auto-generated profile, based on publicly available information

Leo Saldain

Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires Argentina

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AEAndrés Elía
Andrés Elía
LSLeo Saldain
Leo Saldain
SVSilvia I. Vanzulli
Silvia I. Vanzulli
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
CLCaroline A. Lamb
Caroline A. Lamb
CLClaudia Lanari
Claudia Lanari
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast carcinomas that express higher levels of progesterone receptor isoform A (PRA) than isoform B (PRB). Thus, we designed a presurgical window of opportunity trial to determine the therapeutic effects of mifepristone in patients with breast cancer, based on their high PRA/PRB isoform ratio (MIPRA; NCT02651844). Patients and Methods: Twenty patients with luminal breast carcinomas with PRA/PRB > 1.5 (determined by Western blots), and PR ≥ 50%, naïve from previous treatment, were included for mifepristone treatment (200 mg/day orally; 14 days). Core needle biopsies and surgical samples were formalin fixed for IHC studies, while others were snap-frozen to perform RNA sequencing (RNA-seq), proteomics, and/or Western blot studies. Plasma mifepristone levels were determined using mass spectrometry. The primary endpoint was the comparison of Ki67 expression pretreatment and posttreatment. Results: A 49.62% decrease in Ki67 staining was observed in all surgical specimens compared with baseline (P = 0.0003). Using the prespecified response parameter (30% relative reduction), we identified 14 of 20 responders. Mifepristone induced an increase in tumor-infiltrating lymphocytes; a decrease in hormone receptor and pSer118ER expression; and an increase in calregulin, p21, p15, and activated caspase 3 expression. RNA-seq and proteomic studies identified downregulated pathways related to cell proliferation and upregulated pathways related to immune bioprocesses and extracellular matrix remodeling. Conclusions: Our results support the use of mifepristone in patients with luminal breast cancer with high PRA/PRB ratios. The combined effects of mifepristone and estrogen receptor modulators warrant clinical evaluation to improve endocrine treatment responsiveness in these patients. See related commentary by Ronchi and Brisken, p. 833

25 November 2025
Verified
Other
Open access
AEAndrés Elía
Andrés Elía
LSLeo Saldain
Leo Saldain
SVSilvia I. Vanzulli
Silvia I. Vanzulli
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
CLCaroline A. Lamb
Caroline A. Lamb
CLClaudia Lanari
Claudia Lanari
Morphological features after mifepristone treatment. A-D, Images illustrating increased stromal tissue (A), thin and scarce collagen fibers, and increased stromal matrix (arrow; B), an area of tissue remodeling (C), and an area of increased differentiation (D) observed in the surgical samples (S) compared to the respective core needle biopsies (CNB). E, Image illustrates an area of necrosis (dotted arrow) together with a differentiated structure (black arrow) in a surgical sample. F, Cells with Alcian blue+ (left), PAS+ (middle) and MUC-1+ (immunohistochemistry; right) vacuoles observed in a mifepristone-treated tumor. Inset: High power field of a differentiated gland/duct.


25 November 2025
Verified
Other
Open access
AEAndrés Elía
Andrés Elía
LSLeo Saldain
Leo Saldain
SVSilvia I. Vanzulli
Silvia I. Vanzulli
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
CLCaroline A. Lamb
Caroline A. Lamb
CLClaudia Lanari
Claudia Lanari
Evaluation of Ki67 expression in paired samples before and after mifepristone treatment by two independent pathologists, and time elapsed between core needle biopsy and surgery.

25 November 2025
Verified
Other
Open access
AEAndrés Elía
Andrés Elía
LSLeo Saldain
Leo Saldain
SVSilvia I. Vanzulli
Silvia I. Vanzulli
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
CLCaroline A. Lamb
Caroline A. Lamb
CLClaudia Lanari
Claudia Lanari
A, Library size before and after low count filtering. B, P-value histogram distribution observed in the differential expression analysis. C, Pairwise scatter plots of the first five principal components from the principal component analysis of RNA-Seq data.